Skip to content
Pharma Observatory a Scientist.com platform

Source-defined biomarker

Ketamine induced pharmaco-BOLD response as a Pharmacodynamic/Response (PD/R) biomarker for early-stage clinical studies of glutamate-targeted treatments for schizophrenia

This exact source name has not been reconciled to a broader biomarker identity.

Ketamine induced pharmaco-BOLD response as a Pharmacodynamic/Response (PD/R) biomarker for early-stage clinical studies of glutamate-targeted treatments for schizophrenia is a source-defined biomarker in the evidence tier "FDA qualification project". This page lists evidence by type: FDA biomarker qualification projects (1), each linked to its source.

Source-scoped identity
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

FDA companion diagnostic assertions Measured, none recorded FDA biomarker qualification projects 1recorded Assay-provider ledger Measured, none recorded

FDA qualification project

An FDA Biomarker Qualification Program project names this biomarker.

Get the Ketamine induced pharmaco-BOLD response as a Pharmacodynamic/Response (PD/R) biomarker for early-stage clinical studies of glutamate-targeted treatments for schizophrenia report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Source-level evidence only

Gene-level evidence mining does not apply to this kind of biomarker, so the source assertions on this page are the full depth available for it. A section missing below was not measured, and does not mean zero evidence.

FDA biomarker qualification projects (1)

Shown in this order: most recent snapshot first.

FDA biomarker qualification projects
Project DDT number Source status Submitter Biomarker role
Ketamine induced pharmaco-BOLD response as a Pharmacodynamic/Response (PD/R) biomarker for early-stage clinical studies of glutamate-targeted treatments for schizophrenia DDT-BMQ-000125 Project status: Not accepted Columbia Center for Psychiatric Experimental Medicine (CCPEM) Not assigned

Not on this page

Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and assay-provider ledger.

Browse all biomarker evidence pages